EDISON EQUITY RESEARCH - AMARIN

EDISON EQUITY RESEARCH: AMARIN - VASCEPA COGS OILED UNTIL REDUCE-IT REPORTS

 Amarin has responded to a challenging year by focusing on cost control measures and driving the sales launch of Vascepa with copromotion partner Kowa, despite the headwind of generic entrants in the >$1bn US Lovaza market. Initial sales data are encouraging; investors will look for Amarin to manage costs and increase Vascepa market share until the interim readout from the REDUCE-IT Phase III trial, potentially in 2016. 

 Amarin has responded to a challenging year by focusing on cost control measures and driving the sales launch of Vascepa with copromotion partner Kowa, despite the headwind of generic entrants in the >$1bn US Lovaza market. Initial sales data are encouraging; investors will look for Amarin to manage costs and increase Vascepa market share until the interim readout from the REDUCE-IT Phase III trial, potentially in 2016. 

To view our full report, please click here

Click here to view all of Edison Investment Research’s published reports